Literature DB >> 22415435

Mortality and morbidity of nosocomial respiratory syncytial virus (RSV) infection in ventilated children--a ten year perspective.

K Thorburn1, M Eisenhut, A Riordan.   

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) is one of the most common pathogens involved in nosocomial infection in children. The aim of the study was to determine the impact of nosocomial RSV infection on mortality and pediatric intensive care unit (PICU) morbidity of ventilated children.
METHODS: This is a prospective observational cohort study of all children ventilated with RSV infection in a tertiary-referral PICU over a 10-year period. Determinants of the relationship of nosocomial (PICU-acquired and hospital ward-acquired) RSV infection to mortality and PICU morbidity were adjusted for by performing multiple regression analysis.
RESULTS: Of 525 RSV-positive children ventilated on PICU during the ten-year study period, 38 (7.2%) acquired their RSV infection following PICU admission and 38 (7.2%) had acquired RSV in hospital. Ten (26%) children that acquired RSV on PICU died (RR 6.4, 95%CI 3.2-12.9) and 11 (29%) with hospital ward-acquired infection died (RR 9.8, 95%CI 5.1-18.9), compared to 18 (4%) with community-acquired RSV infection. Nosocomial RSV infection was significantly and independently associated with death which was more strongly predicted by immunodeficiency and congenital heart disease (P<0.01). Nosocomial RSV infection was the strongest predictor for morbidity as reflected in duration of ventilation and length of stay on PICU (P<0.01).
CONCLUSION: Nosocomial RSV infection was independently associated with increased mortality and was the strongest predictor of duration of ventilation and length of stay in children on PICU. Decreasing nosocomial RSV infection would reduce deaths in ventilated children.

Entities:  

Mesh:

Year:  2012        PMID: 22415435

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  8 in total

1.  Respiratory syncytial virus (RSV) infection in children with medical complexity.

Authors:  A Lim; M L Butt; J Dix; L Elliott; B Paes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-10-29       Impact factor: 3.267

2.  Characterization of hospital and community-acquired respiratory syncytial virus in children with severe lower respiratory tract infections in Ho Chi Minh City, Vietnam, 2010.

Authors:  Tran Anh Tuan; Tran Tan Thanh; Nguyen thi Thanh Hai; Le Binh Bao Tinh; Le thi Ngoc Kim; Lien Anh Ha Do; Nguyen thi Thuy Chinh B'Krong; Nguyen Thi Tham; Vu thi Ty Hang; Laura Merson; Jeremy Farrar; Tang Chi Thuong; Menno D de Jong; Constance Schultsz; H Rogier van Doorn
Journal:  Influenza Other Respir Viruses       Date:  2015-05       Impact factor: 4.380

Review 3.  Social, economic, and health impact of the respiratory syncytial virus: a systematic search.

Authors:  Javier Díez-Domingo; Eduardo G Pérez-Yarza; José A Melero; Manuel Sánchez-Luna; María Dolores Aguilar; Antonio Javier Blasco; Noelia Alfaro; Pablo Lázaro
Journal:  BMC Infect Dis       Date:  2014-10-30       Impact factor: 3.090

4.  Bronchoscopic interventions with surfactant and recombinant human deoxyribonuclease for acute respiratory distress syndrome-type respiratory syncytial virus-pneumonia in moderately preterm infants: Case series.

Authors:  Martin F Krause; Tobias Ankermann
Journal:  SAGE Open Med Case Rep       Date:  2014-10-08

5.  Viral Specific Factors Contribute to Clinical Respiratory Syncytial Virus Disease Severity Differences in Infants.

Authors:  Tonya M Thompson; Philippa L Roddam; Lisa M Harrison; Jody A Aitken; John P DeVincenzo
Journal:  Clin Microbiol       Date:  2015-06-29

6.  Paramyxoviruses respiratory syncytial virus, parainfluenza virus, and human metapneumovirus infection in pediatric hospitalized patients and climate correlation in a subtropical region of southern China: a 7-year survey.

Authors:  Wen-Kuan Liu; De-Hui Chen; Wei-Ping Tan; Shu-Yan Qiu; Duo Xu; Li Zhang; Shu-Jun Gu; Rong Zhou; Qian Liu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-09-05       Impact factor: 3.267

7.  Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries.

Authors:  Bosco Paes; Ian Mitchell; Abby Li; Tetsuhiro Harimoto; Krista L Lanctôt
Journal:  Clin Dev Immunol       Date:  2013-06-19

Review 8.  Role of viral bioaerosols in nosocomial infections and measures for prevention and control.

Authors:  Yun-Hui Zhang; Nancy H L Leung; Benjamin J Cowling; Zi-Feng Yang
Journal:  J Aerosol Sci       Date:  2017-12-02       Impact factor: 3.433

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.